Post by alice on Aug 31, 2021 10:24:31 GMT -5
About Alzheimer's Disease
News
All Patients in GAIN Trial Show Signs of Gum Disease Bacteria
Marisa Wexler MS avatar
by Marisa Wexler MS | August 30, 2021
Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people with Alzheimer’s disease, showed evidence of infection by Porphyromonas gingivalis (P. gingivalis), according to a new analysis.
In particular, all patients analyzed at the beginning of the study who had available data on their cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — were positive for antibodies against P. gingivalis, supporting a direct P. gingivalis infection in the central nervous system.
The findings add to a growing body of data supporting a link between P. gingivalis — a type of bacteria best known for causing gum (periodontal) disease — and Alzheimer’s.
News
All Patients in GAIN Trial Show Signs of Gum Disease Bacteria
Marisa Wexler MS avatar
by Marisa Wexler MS | August 30, 2021
Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people with Alzheimer’s disease, showed evidence of infection by Porphyromonas gingivalis (P. gingivalis), according to a new analysis.
In particular, all patients analyzed at the beginning of the study who had available data on their cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — were positive for antibodies against P. gingivalis, supporting a direct P. gingivalis infection in the central nervous system.
The findings add to a growing body of data supporting a link between P. gingivalis — a type of bacteria best known for causing gum (periodontal) disease — and Alzheimer’s.
I am no longer able to hold your hand my beloved but I cherish the remembrance of your hand in mine...and the wonderful person that touched so many lives with joy. : )